CSL Limited
Market Cap
$55.2B
Global Rank
#245
All-Time High
$85.2B
2023-12-31
Total Growth
+0%
since 2026
Market Cap Context
- Larger than 33% of the 367 companies we track (globally).
- Equivalent to 3.1% of Australia's GDP (2025 data).
- Just above: #244 Sea Limited ($56.4B)
- Just below: #246 Nokia Oyj ($55.2B)
- Best year: 2000 (+80%). Worst year: 2002 (-58%).
CSL Limited Financial Breakdown (FY 2025)
Source: Yahoo Finance โ CSL.AX annual filings (2025) โ$15.4B revenue ยท $3.0B operating income ยท $3.0B net income
- โOperating margin: 19.2% on $15.4B in revenue.
- โR&D is 8.8% of revenue ($1.4B).
- โNet income margin: 19.5% โ $3.0B in profit.
- โFree cash flow: $2.5B (16.5% of revenue).
Cost / Operating Expenses
Total operating expenses $12.5B
Total
$11.5B
Capital Expenditures
$1.0B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$2.5B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
About CSL Limited
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
CSL Limited Market Cap History (2026โ2026)
CSL Limited vs Sector Peers by Market Cap
Compare CSL Limited
Ranking History
| Year | Market Cap | Rank | YoY Change |
|---|---|---|---|
| 2026 | $55.2B | #245(โ4) | +4.0% |
| 2025 | $53.1B | #241(โ91) | -37.5% |
| 2024 | $84.9B | #150(โ16) | -0.4% |
| 2023 | $85.2B | #134(โ24) | +0.9% |
| 2022 | $84.5B | #110(โ11) | +0.1% |
| 2021 | $84.4B | #121(โ17) | +3.7% |
| 2020 | $81.3B | #104(โ17) | +3.7% |
| 2019 | $78.4B | #87(โ10) | +50.8% |
| 2018 | $52.0B | #97(โ47) | +32.6% |
| 2017 | $39.2B | #144(โ20) | +42.7% |
| 2016 | $27.5B | #164(โ21) | -3.0% |
| 2015 | $28.3B | #143(โ26) | +23.7% |
| 2014 | $22.9B | #169(โ16) | +27.9% |
| 2013 | $17.9B | #185(โ11) | +30.1% |
| 2012 | $13.8B | #174(โ31) | +72.1% |
| 2011 | $8.0B | #205(โ2) | -9.4% |
| 2010 | $8.8B | #207(โ3) | +14.4% |
| 2009 | $7.7B | #204(โ41) | -1.6% |
| 2008 | $7.9B | #163(โ36) | -6.1% |
| 2007 | $8.4B | #199(โ27) | +68.8% |
| 2006 | $5.0B | #226(โ10) | +55.9% |
| 2005 | $3.2B | #236(โ2) | +47.7% |
| 2004 | $2.2B | #238(โ3) | +66.3% |
| 2003 | $1.3B | #241(โ22) | -15.6% |
| 2002 | $1.5B | #219(โ34) | -57.5% |
| 2001 | $3.6B | #185(โ2) | +32.6% |
| 2000 | $2.7B | #187(โ21) | +79.9% |
| 1999 | $1.5B | #166(โ2) | +58.6% |
| 1998 | $954.6M | #168(โ1) | +48.3% |
| 1997 | $643.5M | #169(โ4) | +64.6% |
| 1996 | $391.0M | #165(โ12) | +52.3% |
| 1995 | $256.7M | #153(โ14) | +71.4% |
| 1994 | $149.8M | #139 |
Other Healthcare Companies
FAQ
What is CSL Limited's market cap?
CSL Limited (CSL.AX) has a market capitalization of $55.2B, making it the #245 largest company in the world by market cap.
What was CSL Limited's highest market cap?
CSL Limited's all-time high market cap was $85.2B, reached in 2023-12-31. Its highest rank was #134 in 2023.
What sector is CSL Limited in?
CSL Limited is in the Healthcare sector, specifically the Biotechnology industry. It is based in Australia.
How has CSL Limited's market cap changed over time?
CSL Limited has been tracked since 2026. Its market cap has grown by 0% from $55.2B in 2026 to $55.2B today.